{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:26:44Z","timestamp":1773797204129,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Relugolix, an oral gonadotrophin-releasing hormone receptor antagonist, was launched in Japan in 2019. Although there have been several studies on relugolix for leiomyomas, few have focused on submucosal leiomyomas. Submucosal leiomyomas cause bleeding more frequently than leiomyomas in other locations. There is only one case report described a patient treated for a submucosal leiomyoma with relugolix who developed severe hemorrhage. However, it remains unclear which characteristics of submucosal leiomyomas can lead to severe hemorrhage. Thus, the aim of this study was to investigate the characteristics of submucosal leiomyomas that would cause severe hemorrhage when treated with relugolix.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively reviewed records of patients who underwent treatment for submucosal leiomyoma with relugolix (40\u00a0mg once daily for up to 6\u00a0months) in our institute between December 2019 and September 2021. We evaluated the clinical course and characteristics of submucosal leiomyoma in patients who developed severe hemorrhage.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 17 patients were treated for submucosal leiomyoma with relugolix. Two patients developed severe hemorrhage and required emergent surgery and blood transfusions. Only those two of the 17 patients had a submucosal leiomyoma of the International Federation of Gynecology and Obstetrics (FIGO) type 0, which has a stalk. In the remaining 15 patients who had FIGO type 1 or 2 leiomyoma, hemorrhage did not occur.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study suggests that the use of relugolix for FIGO type 0 leiomyomas may be associated with a risk of hemorrhage. However, relugolix may be a safe and effective treatment option for patients with FIGO type 1 or 2 leiomyomas.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-023-02241-2","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T10:03:35Z","timestamp":1678874615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characteristics of submucosal leiomyomas that could cause severe hemorrhage with relugolix: an observational study"],"prefix":"10.1186","volume":"23","author":[{"given":"Yoshimitsu","family":"Wada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Minezumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Hirashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"2241_CR1","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0029-7844(97)00534-6","volume":"90","author":"LM Marshall","year":"1997","unstructured":"Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997;90:967\u201373.","journal-title":"Obstet Gynecol"},{"key":"2241_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/AOG.0000000000003141","volume":"133","author":"Y Osuga","year":"2019","unstructured":"Osuga Y, Enya K, Kudou K, Tanimoto M, Hoshiai H. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2019;133:423\u201333.","journal-title":"Obstet Gynecol"},{"key":"2241_CR3","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/j.fertnstert.2008.03.029","volume":"93","author":"BW Rackow","year":"2010","unstructured":"Rackow BW, Taylor HS. Submucosal uterine leiomyomas have a global effect on molecular determinants of endometrial receptivity. Fertil Steril. 2010;93:2027\u201334.","journal-title":"Fertil Steril"},{"key":"2241_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ajog.2013.09.038","volume":"210","author":"K Puri","year":"2014","unstructured":"Puri K, Famuyide AO, Erwin PJ, Stewart EA, Laughlin-Tommaso SK. Submucosal fibroids and the relation to heavy menstrual bleeding and anemia. Am J Obstet Gynecol. 2014;210:38.","journal-title":"Am J Obstet Gynecol"},{"key":"2241_CR5","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.fertnstert.2019.07.013","volume":"112","author":"Y Osuga","year":"2019","unstructured":"Osuga Y, Enya K, Kudou K, Hoshiai H. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women. Fertil Steril. 2019;112:922\u20139.","journal-title":"Fertil Steril"},{"key":"2241_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12905-021-01475-2","volume":"21","author":"H Hoshiai","year":"2021","unstructured":"Hoshiai H, Seki Y, Kusumoto T, Kudou K, Tanimoto M. Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial. BMC Womens Health. 2021;21:375.","journal-title":"BMC Womens Health"},{"key":"2241_CR7","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1056\/NEJMoa2008283","volume":"384","author":"A Al-Hendy","year":"2021","unstructured":"Al-Hendy A, Lukes AS, Poindexter AN, Venturella R, Villarroel C, Critchley HOD, et al. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. N Engl J Med. 2021;384:630\u201342.","journal-title":"N Engl J Med"},{"key":"2241_CR8","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1097\/AOG.0000000000004787","volume":"139","author":"EA Stewart","year":"2022","unstructured":"Stewart EA, Lukes AS, Venturella R, Arjona Ferreira J-C, Li Y, Hunsche E, et al. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials. Obstet Gynecol. 2022;139:1070\u201381.","journal-title":"Obstet Gynecol"},{"key":"2241_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/jog.14479","author":"C Ishizawa","year":"2020","unstructured":"Ishizawa C, Hirota Y, Urata Y, Morishima K, Fujii T, Osuga Y. Prolapse of a pedunculated uterine leiomyoma through the cervix during GnRH antagonist treatment: Case report and literature review. J Obstet Gynaecol Res. 2020. https:\/\/doi.org\/10.1111\/jog.14479.","journal-title":"J Obstet Gynaecol Res"},{"key":"2241_CR10","unstructured":"ASKA Pharmaceutical Co., Ltd. Requests for proper use for patients with submucosal uterine myoma. https:\/\/www.aska-pharma.co.jp\/english\/. Accessed 8 Aug 2022."},{"key":"2241_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ijgo.12666","volume":"143","author":"MG Munro","year":"2018","unstructured":"Munro MG, Critchley HOD, Fraser IS, FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393\u2013408.","journal-title":"Int J Gynaecol Obstet"},{"key":"2241_CR12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/uog.3832","volume":"28","author":"C Lee","year":"2006","unstructured":"Lee C, Salim R, Ofili-Yebovi D, Yazbek J, Davies A, Jurkovic D. Reproducibility of the measurement of submucous fibroid protrusion into the uterine cavity using three-dimensional saline contrast sonohysterography. Ultrasound Obstet Gynecol. 2006;28:837\u201341.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2241_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/jog.15269","author":"A Takeda","year":"2022","unstructured":"Takeda A. Short-term administration of oral relugolix before single-port laparoscopic-assisted vaginal hysterectomy for symptomatic uterine myomas: A retrospective comparative study with leuprorelin injection. J Obstet Gynaecol Res. 2022. https:\/\/doi.org\/10.1111\/jog.15269.","journal-title":"J Obstet Gynaecol Res"},{"key":"2241_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1479-828X.1991.tb02831.x","volume":"31","author":"T Chipato","year":"1991","unstructured":"Chipato T, Healy DL, Vollenhoven B, Buckler HM. Pelvic pain complicating LHRH analogue treatment of fibroids. Aust N Z J Obstet Gynaecol. 1991;31:383\u20134.","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"2241_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0140-6736(89)90235-3","volume":"2","author":"A Ellenbogen","year":"1989","unstructured":"Ellenbogen A, Shulman A, Libal Y, Jaschevatzky O, Anderman S, Grunstein S. Complication of triptorelin treatment for uterine myomas. Lancet. 1989;2:167\u20138.","journal-title":"Lancet"},{"key":"2241_CR16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/014436102320261221","volume":"22","author":"A Kriplani","year":"2002","unstructured":"Kriplani A, Agarwal N, Parul D, Bhatla N, Saxena AK. Prolapsed leiomyoma with severe haemorrhage after GnRH analogue therapy. J Obstet Gynaecol. 2002;22:449\u201351.","journal-title":"J Obstet Gynaecol"},{"key":"2241_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S1028-4559(09)60220-5","volume":"45","author":"L Wen","year":"2006","unstructured":"Wen L, Tseng J-Y, Wang P-H. Vaginal expulsion of a submucosal myoma during treatment with long-acting gonadotropin-releasing hormone agonist. Taiwan J Obstet Gynecol. 2006;45:173\u20135.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"2241_CR18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S0015-0282(01)01900-8","volume":"76","author":"M Dueholm","year":"2001","unstructured":"Dueholm M, Lundorf E, Hansen ES, Ledertoug S, Olesen F. Evaluation of the uterine cavity with magnetic resonance imaging, transvaginal sonography, hysterosonographic examination, and diagnostic hysteroscopy. Fertil Steril. 2001;76:350\u20137.","journal-title":"Fertil Steril"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-023-02241-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-023-02241-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-023-02241-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T10:03:50Z","timestamp":1678874630000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-023-02241-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2241"],"URL":"https:\/\/doi.org\/10.1186\/s12905-023-02241-2","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"assertion":[{"value":"27 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was approved by the ethics committee of Sano Kosei General Hospital [approval number: 202120 (Feb. 7th, 2022)]. There is no need for written consent to participate to be obtained because this study is a retrospective study. We informed patients of this study using an opt-out approach. The opt-out approach was approved by the ethics committee of Sano Kosei General Hospital. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors YW and HH received payments for lectures at educational events from Aska pharmaceutical Co., Ltd. The funding source played no role in the design, practice, or analysis of this study. Remaining all authors don't have any Competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}